| Year |
Citation |
Score |
| 2024 |
Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, Santana JF, Miklavcic WR, LaBreck DA, Mallareddy JR, Price DH, Natarajan A, Mehla K, Sykes DB, Hollingsworth MA, ... Singh PK, et al. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Elife. 12. PMID 38973593 DOI: 10.7554/eLife.87292 |
0.529 |
|
| 2024 |
Murthy D, Attri KS, Shukla SK, Thakur R, Chaika NV, He C, Wang D, Jha K, Dasgupta A, King RJ, Mulder SE, Souchek J, Gebregiworgis T, Rai V, Patel R, ... ... Singh PK, et al. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Nature Cell Biology. PMID 38641662 DOI: 10.1038/s41556-024-01417-8 |
0.58 |
|
| 2024 |
Murthy D, Attri KS, Suresh V, Rajacharya GH, Valenzuela CA, Thakur R, Zhao J, Shukla SK, Chaika NV, LaBreck D, Rao CV, Hollingsworth MA, Mehla K, Singh PK. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proceedings of the National Academy of Sciences of the United States of America. 121: e2315509121. PMID 38547055 DOI: 10.1073/pnas.2315509121 |
0.61 |
|
| 2024 |
Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, et al. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Science Signaling. 17: eadh4475. PMID 38442201 DOI: 10.1126/scisignal.adh4475 |
0.348 |
|
| 2024 |
Murthy D, Attri KS, Shukla SK, Thakur R, Chaika NV, He C, Wang D, Jha K, Dasgupta A, King RJ, Mulder SE, Souchek J, Gebregiworgis T, Rai V, Patel R, ... ... Singh PK, et al. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Nature Cell Biology. PMID 38429478 DOI: 10.1038/s41556-024-01372-4 |
0.583 |
|
| 2024 |
Chumak V, Rajacharya GH, Singh PK. Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells. Methods in Molecular Biology (Clifton, N.J.). 2755: 191-200. PMID 38319579 DOI: 10.1007/978-1-0716-3633-6_14 |
0.318 |
|
| 2023 |
Singh PK, Mehla K. LXR Signaling-Mediated Cholesterol Metabolism Reprogramming Regulates Cancer Cell Metastasis. Cancer Research. 83: 1759-1761. PMID 37264829 DOI: 10.1158/0008-5472.CAN-23-0624 |
0.347 |
|
| 2023 |
Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, LaBreck DA, Mallareddy JR, Price DH, Natarajan A, Mehla K, Sykes DB, Hollingsworth MA, Singh PK. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Biorxiv : the Preprint Server For Biology. PMID 37066260 DOI: 10.1101/2023.04.03.535399 |
0.527 |
|
| 2023 |
Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nature Reviews. Cancer. 23: 275-294. PMID 36973407 DOI: 10.1038/s41568-023-00557-7 |
0.361 |
|
| 2022 |
Mullen NJ, Thakur R, Shukla SK, Chaika NV, Kollala SS, Wang D, He C, Fujii Y, Sharma S, Mulder SE, Sykes DB, Singh PK. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer Letters. 552: 215981. PMID 36341997 DOI: 10.1016/j.canlet.2022.215981 |
0.312 |
|
| 2022 |
Gupta K, Jones JC, Farias VA, Mackeyev Y, Singh PK, Quiñones-Hinojosa A, Krishnan S. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. Frontiers in Oncology. 12: 840241. PMID 35664781 DOI: 10.3389/fonc.2022.840241 |
0.327 |
|
| 2022 |
Xu PC, You M, Yu SY, Luan Y, Eldani M, Caffrey TC, Grandgenett PM, O'Connell KA, Shukla SK, Kattamuri C, Hollingsworth MA, Singh PK, Thompson TB, Chung S, Kim SY. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Scientific Reports. 12: 1659. PMID 35102236 DOI: 10.1038/s41598-022-05660-7 |
0.43 |
|
| 2022 |
King RJ, Shukla SK, He C, Vernucci E, Thakur R, Attri KS, Dasgupta A, Chaika NV, Mulder SE, Abrego J, Murthy D, Gunda V, Pacheco CG, Grandgenett PM, Lazenby AJ, ... ... Singh PK, et al. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. PMID 35001076 DOI: 10.1038/s41388-021-02132-6 |
0.485 |
|
| 2021 |
Markov SD, Caffrey TC, O' Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, ... Singh PK, et al. IgE-based therapeutic combination enhances anti-tumor response in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics. PMID 34625505 DOI: 10.1158/1535-7163.MCT-21-0368 |
0.534 |
|
| 2021 |
King RJ, Qiu F, Yu F, Singh PK. Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities. Frontiers in Cell and Developmental Biology. 9: 667852. PMID 34307352 DOI: 10.3389/fcell.2021.667852 |
0.321 |
|
| 2021 |
Lin S, Li Y, Wang D, Huang C, Marino D, Bollt O, Wu C, Taylor MD, Li W, DeNicola GM, Hao J, Singh PK, Yang S. Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. Cancer Letters. 518: 230-242. PMID 34303764 DOI: 10.1016/j.canlet.2021.07.025 |
0.381 |
|
| 2021 |
Hu T, Shukla SK, Vernucci E, He C, Wang D, King RJ, Jha K, Siddhanta K, Mullen NJ, Attri KS, Murthy D, Chaika NV, Thakur R, Mulder SE, Pacheco CG, ... ... Singh PK, et al. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-induced Pancreatic Cancer Progression. Gastroenterology. PMID 34245764 DOI: 10.1053/j.gastro.2021.06.045 |
0.334 |
|
| 2021 |
Gupta VK, Sharma NS, Durden B, Garrido VT, Kesh K, Edwards D, Wang D, Myer C, Mateo-Victoriano B, Kollala SS, Ban Y, Gao Z, Bhattacharya SK, Saluja A, Singh PK, et al. Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune evasion in pancreatic cancer. Cancer Research. PMID 33990397 DOI: 10.1158/0008-5472.CAN-20-2562 |
0.324 |
|
| 2020 |
Mulder SE, Dasgupta A, King RJ, Abrego J, Attri KS, Murthy D, Shukla SK, Singh PK. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. Cancer Letters. PMID 32735910 DOI: 10.1016/J.Canlet.2020.07.025 |
0.422 |
|
| 2020 |
DelGiorno KE, Chung CY, Vavinskaya V, Maurer HC, Novak SW, Lytle NK, Ma Z, Giraddi RR, Wang D, Fang L, Naeem RF, Andrade LR, Ali WH, Tseng H, Tsui C, ... ... Singh PK, et al. Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2. Gastroenterology. PMID 32717220 DOI: 10.1053/J.Gastro.2020.07.037 |
0.378 |
|
| 2020 |
Lin S, Taylor MD, Singh PK, Yang S. How Does Fascin Promote Cancer Metastasis? The Febs Journal. PMID 32657526 DOI: 10.1111/febs.15484 |
0.351 |
|
| 2020 |
Mundry C, Eberle KC, Singh PK, Hollingsworth MA, Mehla K. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Biochimica Et Biophysica Acta. Reviews On Cancer. 188387. PMID 32579889 DOI: 10.1016/J.Bbcan.2020.188387 |
0.478 |
|
| 2020 |
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Singh PK, et al. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 32483362 DOI: 10.1038/S41591-020-0947-8 |
0.397 |
|
| 2020 |
Dasgupta A, Shukla SK, Vernucci E, King RJ, Abrego J, Mulder SE, Mullen NJ, Graves G, Buettner K, Thakur R, Murthy D, Attri KS, Wang D, Chaika NV, Pacheco CG, ... ... Singh PK, et al. SIRT1-NOX4 signaling axis regulates cancer cachexia. The Journal of Experimental Medicine. 217. PMID 32441762 DOI: 10.1084/Jem.20190745 |
0.599 |
|
| 2020 |
Shukla SK, Markov SD, Attri KS, Vernucci E, King RJ, Dasgupta A, Grandgenett PM, Hollingsworth MA, Singh PK, Yu F, Mehla K. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Letters. PMID 32344015 DOI: 10.1016/J.Canlet.2020.04.017 |
0.517 |
|
| 2019 |
Vernucci E, Abrego J, Gunda V, Shukla SK, Dasgupta A, Rai V, Chaika N, Buettner K, Illies A, Yu F, Lazenby AJ, Swanson BJ, Singh PK. Metabolic Alterations in Pancreatic Cancer Progression. Cancers. 12. PMID 31861288 DOI: 10.3390/Cancers12010002 |
0.633 |
|
| 2019 |
Hsieh MH, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M, Gerold H, Nowak C, Do H, Mazambani S, Knighton JK, Cha M, Goodwin J, Kang MK, Jeong JY, ... ... Singh PK, et al. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports. 28: 1860-1878.e9. PMID 31412252 DOI: 10.1016/J.Celrep.2019.07.027 |
0.32 |
|
| 2019 |
Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, Krishnan S. Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation. Molecular Cancer Therapeutics. PMID 31395686 DOI: 10.1158/1535-7163.MCT-18-0708 |
0.349 |
|
| 2019 |
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Singh PK, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 30833752 DOI: 10.1038/S41591-019-0368-8 |
0.37 |
|
| 2019 |
Shukla SK, Dasgupta A, Mulder SE, Singh PK. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. Methods in Molecular Biology (Clifton, N.J.). 1882: 321-333. PMID 30378066 DOI: 10.1007/978-1-4939-8879-2_28 |
0.433 |
|
| 2019 |
Dasgupta A, Shukla SK, Gunda V, King RJ, Singh PK. Evaluating the Metabolic Alterations in Pancreatic Cancer. Methods in Molecular Biology (Clifton, N.J.). 1882: 221-228. PMID 30378058 DOI: 10.1007/978-1-4939-8879-2_20 |
0.454 |
|
| 2019 |
Pan C, Leiton CV, Roa-Peña L, Kawalerski RR, Moffitt RA, Zhao J, Spicer T, Bailey P, Chang DK, Biankin A, Duong T, Singh PK, Shroyer KR, Escobar-Hoyos LF. Abstract C39: A novel rewired pathway of nucleotide metabolism drives chemoresistance in pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C39 |
0.383 |
|
| 2019 |
Lin S, Huang C, Sun J, Wang X, Kang J, Taylor M, Fang B, Singh PK, Koomen J, Hao J, Yang S. Abstract 973: The mitochondrial deoxyguanosine kinase regulates lung adenocarcinoma cancer stem-like cells through AMPK/YAP1 signaling Cancer Research. 79: 973-973. DOI: 10.1158/1538-7445.Am2019-973 |
0.436 |
|
| 2019 |
Olou A, Mehla K, Singh P. Abstract 1160: Endoplasmic reticulum stress disrupts stemness-related transcriptional regulatory network: Implication for therapy response in cancer Cancer Research. 79: 1160-1160. DOI: 10.1158/1538-7445.Am2019-1160 |
0.413 |
|
| 2018 |
Gebregiworgis T, Bhinderwala F, Purohit V, Chaika NV, Singh PK, Powers R. Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics : Official Journal of the Metabolomic Society. 14: 156. PMID 30830412 DOI: 10.1007/S11306-018-1452-7 |
0.338 |
|
| 2018 |
Murthy D, Attri KS, Singh PK. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Frontiers in Physiology. 9: 335. PMID 29670543 DOI: 10.3389/fphys.2018.00335 |
0.304 |
|
| 2018 |
Attri KS, Mehla K, Singh PK. Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia. Methods in Molecular Biology (Clifton, N.J.). 1742: 265-276. PMID 29330807 DOI: 10.1007/978-1-4939-7665-2_23 |
0.378 |
|
| 2018 |
Shukla SK, Mulder SE, Singh PK. Hypoxia-Mediated In Vivo Tumor Glucose Uptake Measurement and Analysis. Methods in Molecular Biology (Clifton, N.J.). 1742: 107-113. PMID 29330794 DOI: 10.1007/978-1-4939-7665-2_10 |
0.363 |
|
| 2018 |
Gunda V, Kumar S, Dasgupta A, Singh PK. Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. Methods in Molecular Biology (Clifton, N.J.). 1742: 95-105. PMID 29330793 DOI: 10.1007/978-1-4939-7665-2_9 |
0.409 |
|
| 2018 |
Murthy D, Vernucci E, Goode G, Abrego J, Singh PK. Evaluating the Metabolic Impact of Hypoxia on Pancreatic Cancer Cells. Methods in Molecular Biology (Clifton, N.J.). 1742: 81-93. PMID 29330792 DOI: 10.1007/978-1-4939-7665-2_8 |
0.43 |
|
| 2018 |
Shukla SK, King RJ, Singh PK. Transcriptional Profiling Using RNA-Seq to Study Hypoxia-Mediated Gene Regulation. Methods in Molecular Biology (Clifton, N.J.). 1742: 55-66. PMID 29330790 DOI: 10.1007/978-1-4939-7665-2_6 |
0.303 |
|
| 2018 |
Murthy D, Abrego J, King RJ, Singh PK. Abstract 5132: Lactic acidosis-mediated transcriptomic and metabolomic rewiring in pancreatic cancer cells Cancer Research. 78: 5132-5132. DOI: 10.1158/1538-7445.Am2018-5132 |
0.455 |
|
| 2018 |
Shukla SK, Chaika NV, Singh PK. Abstract 3557: Beta-hydroxybutyrate inhibits oncogenic signaling and cellular motility in pancreatic cancer cells Cancer Research. 78: 3557-3557. DOI: 10.1158/1538-7445.Am2018-3557 |
0.48 |
|
| 2017 |
Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29204701 DOI: 10.1007/S00262-017-2095-7 |
0.759 |
|
| 2017 |
King RJ, Yu F, Singh PK. Genomic alterations in mucins across cancers. Oncotarget. 8: 67152-67168. PMID 28978023 DOI: 10.18632/Oncotarget.17934 |
0.456 |
|
| 2017 |
Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, ... ... Singh PK, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 32: 392. PMID 28898700 DOI: 10.1016/J.Ccell.2017.08.008 |
0.513 |
|
| 2017 |
Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, CHaika N, Yu F, Lazenby AJ, Berim L, Grem JL, Sasson A, Singh PK. De Novo Lipid Synthesis facilitates Gemcitabine Resistance Through Endoplasmic Reticulum Stress In Pancreatic Cancer. Cancer Research. PMID 28811332 DOI: 10.1158/0008-5472.CAN-16-3062 |
0.364 |
|
| 2017 |
Gunda V, Souchek JJ, Abrego J, Shukla SK, Goode GD, Vernucci E, Dasgupta A, CHaika N, King RJ, Li S, Wang S, Yu F, Bessho T, Lin C, Singh PK. MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28720669 DOI: 10.1158/1078-0432.Ccr-17-1151 |
0.309 |
|
| 2017 |
Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, ... ... Singh PK, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 32: 71-87.e7. PMID 28697344 DOI: 10.1016/J.Ccell.2017.06.004 |
0.63 |
|
| 2017 |
King RJ, Yu F, Singh PK. Genomic alterations in mucins across cancers. Oncotarget. PMID 28575854 DOI: 10.18632/oncotarget.17934 |
0.351 |
|
| 2017 |
Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, ... ... Singh PK, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications. 8: 15503. PMID 28548087 DOI: 10.1038/Ncomms15503 |
0.329 |
|
| 2017 |
Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK. MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. Plos One. 12: e0176820. PMID 28464016 DOI: 10.1371/Journal.Pone.0176820 |
0.436 |
|
| 2017 |
Kumar A, Sirohi VK, Anum F, Singh PK, Gupta K, Gupta D, Saraf SA, Dwivedi A, Chourasia MK. Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 28457934 DOI: 10.1016/j.nano.2017.04.014 |
0.328 |
|
| 2017 |
Abrego J, Gunda V, Vernucci E, Shukla SK, King RJ, Dasgupta A, Goode G, Murthy D, Yu F, Singh PK. GOT1-Mediated Anaplerotic Glutamine Metabolism Regulates Chronic Acidosis Stress In Pancreatic Cancer Cells. Cancer Letters. PMID 28455244 DOI: 10.1016/J.Canlet.2017.04.029 |
0.353 |
|
| 2017 |
Attri KS, Murthy D, Singh PK. Racial disparity in metabolic regulation of cancer. Frontiers in Bioscience (Landmark Edition). 22: 1221-1246. PMID 28199202 DOI: 10.2741/4543 |
0.434 |
|
| 2017 |
Dasgupta A, Shukla SK, Gunda V, Chaika NV, Singh PK. Abstract LB-267: Metabolic alterations in tumors cause cachexia in pancreatic cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-267 |
0.491 |
|
| 2017 |
Goode GD, Gunda V, Singh P. Abstract 4413: Targeting glutamine metabolism in MUC1 expressing triple negative breast cancer Cancer Research. 77: 4413-4413. DOI: 10.1158/1538-7445.Am2017-4413 |
0.451 |
|
| 2017 |
Vernucci E, Gunda V, Shukla S, Singh PK. Abstract 3542: Coordination of glutamine and glucose metabolism in pancreatic cancer Cancer Research. 77: 3542-3542. DOI: 10.1158/1538-7445.Am2017-3542 |
0.484 |
|
| 2016 |
Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, Yang S, Ogura J, Ganapathy V, Bhutia YD. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. British Journal of Pharmacology. PMID 27747870 DOI: 10.1111/Bph.13616 |
0.392 |
|
| 2016 |
Divakar SA, Reddy MVR, Cosenza SC, Baker SJ, Purohit V, Gunda V, Singh PK, Reddy EP. Abstract 3029: Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinoma Cancer Research. 76: 3029-3029. DOI: 10.1158/1538-7445.Am2016-3029 |
0.458 |
|
| 2016 |
Goode GD, Chaika N, Purohit V, Gunda V, Singh P. Abstract 1152: MUC1: A metabolic regulator in triple-negative breast cancer Cancer Research. 76: 1152-1152. DOI: 10.1158/1538-7445.Am2016-1152 |
0.459 |
|
| 2016 |
Abrego J, Gunda V, Singh PK, Goode G. Abstract 1059: Pancreatic cancer cells acclimatize to low pH by increasing glutamine metabolism Cancer Research. 76: 1059-1059. DOI: 10.1158/1538-7445.Am2016-1059 |
0.412 |
|
| 2016 |
Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Soucheck J, Goode G, King R, Mishra A, Rai I, Natrajan S, Chaika N, Yu F, Singh PK. Abstract 10: Silibinin exhibits anti-cachectic and anti-cancerous property by modulating metabolic properties of pancreatic cancer cells Cancer Research. 76: 10-10. DOI: 10.1158/1538-7445.Am2016-10 |
0.533 |
|
| 2015 |
Mondal G, Kumar V, Shukla SK, Singh PK, Mahato RI. EGFR Targeted Polymeric Mixed Micelles carrying Gemcitabine for treating Pancreatic Cancer. Biomacromolecules. PMID 26626700 DOI: 10.1021/Acs.Biomac.5B01419 |
0.345 |
|
| 2015 |
Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J, Goode G, King R, Mishra A, Rai I, Nagarajan S, Chaika NV, Yu F, Singh PK. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. PMID 26510913 DOI: 10.18632/Oncotarget.5843 |
0.54 |
|
| 2015 |
Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, Song W, Dong J. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. PMID 26440309 DOI: 10.18632/Oncotarget.5935 |
0.516 |
|
| 2015 |
Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J, Chaika NV, Yu F, Sasson AR, Lazenby AJ, Batra SK, Singh PK. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget. PMID 26046375 DOI: 10.18632/Oncotarget.4078 |
0.518 |
|
| 2015 |
Bhutia YD, Babu E, Singh PK, Ganapathy V. Abstract 348: Amino acid-based prodrugs of gemcitabine - a therapeutic option to overcome chemoresistance in pancreatic cancer Cancer Research. 75: 348-348. DOI: 10.1158/1538-7445.Am2015-348 |
0.442 |
|
| 2014 |
Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer & Metabolism. 2: 18. PMID 25228990 DOI: 10.1186/2049-3002-2-18 |
0.45 |
|
| 2014 |
Liu X, Caffrey TC, Steele MM, Mohr A, Singh PK, Radhakrishnan P, Kelly DL, Wen Y, Hollingsworth MA. MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin. Oncogenesis. 3: e107. PMID 24979278 DOI: 10.1038/oncsis.2014.19 |
0.636 |
|
| 2014 |
Stark JL, Mehla K, Chaika N, Acton TB, Xiao R, Singh PK, Montelione GT, Powers R. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry. 53: 1360-72. PMID 24512202 DOI: 10.1021/Bi401329A |
0.461 |
|
| 2014 |
Mehla K, Singh PK. MUC1: a novel metabolic master regulator. Biochimica Et Biophysica Acta. 1845: 126-35. PMID 24418575 DOI: 10.1016/J.Bbcan.2014.01.001 |
0.423 |
|
| 2014 |
Shukla SK, Singh PK. Abstract 3376: Targeting metabolic flux of tumor cells to prevent pancreatic cancer associated cachexia Cancer Research. 74: 3376-3376. DOI: 10.1158/1538-7445.Am2014-3376 |
0.515 |
|
| 2013 |
Purohit V, Chaika NV, Gebregiworgis T, Radhakrishnan P, Zhang B, Mehla K, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK. Abstract 5391: MUC1 and HIF-1α signaling interactions modulate glucose flux in pancreatic cancer. Cancer Research. 73: 5391-5391. DOI: 10.1158/1538-7445.Am2013-5391 |
0.62 |
|
| 2012 |
Dey P, Rachagani S, Chakraborty S, Singh PK, Zhao X, Gurumurthy CB, Anderson JM, Lele S, Hollingsworth MA, Band V, Batra SK. Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6188-98. PMID 22977192 DOI: 10.1158/1078-0432.Ccr-12-1789 |
0.634 |
|
| 2012 |
Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, Zhang B, Mehla K, Brown RB, Caffrey T, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 13787-92. PMID 22869720 DOI: 10.1073/Pnas.1203339109 |
0.804 |
|
| 2012 |
Singh PK, Brand RE, Mehla K. MicroRNAs in pancreatic cancer metabolism. Nature Reviews. Gastroenterology & Hepatology. 9: 334-44. PMID 22508159 DOI: 10.1038/Nrgastro.2012.63 |
0.351 |
|
| 2012 |
Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, Batra SK. Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Letters. 323: 29-40. PMID 22475682 DOI: 10.1016/J.Canlet.2012.03.031 |
0.471 |
|
| 2012 |
Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, Singh PK. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. Plos One. 7: e32996. PMID 22412968 DOI: 10.1371/Journal.Pone.0032996 |
0.627 |
|
| 2012 |
Purohit V, Chaika NV, Gebregiworgis TG, Powers R, Johnson KR, Hollingsworth MA, Singh PK. Abstract 5152: Targeting HIF1α-mediated metabolic alterations in pancreatic cancer Cancer Research. 72: 5152-5152. DOI: 10.1158/1538-7445.Am2012-5152 |
0.611 |
|
| 2011 |
Singh PK, Mehla K, Hollingsworth MA, Johnson KR. Regulation of Aerobic Glycolysis by microRNAs in Cancer. Molecular and Cellular Pharmacology. 3: 125-134. PMID 22792411 DOI: 10.4255/Mcpharmacol.11.17 |
0.584 |
|
| 2011 |
Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6140-50. PMID 21825040 DOI: 10.1158/1078-0432.Ccr-10-2288 |
0.732 |
|
| 2010 |
Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, Hollingsworth MA. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene. 29: 5667-77. PMID 20697347 DOI: 10.1038/Onc.2010.327 |
0.667 |
|
| 2010 |
Behrens M, Grandgenett P, Bailey J, Singh P, Yi C, Hollingsworth M. Abstract 5077: Signaling through the cytoplasmic tail of MUC1 directly activates transcription of the metastasis promoting growth factor CTGF in pancreatic adenocarcinoma Cancer Research. 70: 5077-5077. DOI: 10.1158/1538-7445.Am10-5077 |
0.715 |
|
| 2008 |
Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5995-6004. PMID 18829478 DOI: 10.1158/1078-0432.Ccr-08-0291 |
0.793 |
|
| 2008 |
Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. The Journal of Biological Chemistry. 283: 26985-95. PMID 18625714 DOI: 10.1074/Jbc.M805036200 |
0.722 |
|
| 2008 |
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Research. 68: 2065-70. PMID 18381409 DOI: 10.1158/0008-5472.Can-07-6041 |
0.639 |
|
| 2008 |
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells (Cancer Research (April 1, 2008) 68(2065-2070)) Cancer Research. 68: 3549. DOI: 10.1158/0008-5472.Can-68-9-Cor3 |
0.575 |
|
| 2008 |
Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion (Cancer Research (2007) 67, (10222-10229)) Cancer Research. 68: 338. DOI: 10.1158/0008-5472.Can-68-1-Cor |
0.775 |
|
| 2007 |
Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Research. 67: 10222-9. PMID 17974963 DOI: 10.1158/0008-5472.Can-06-2483 |
0.783 |
|
| 2007 |
Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. Journal of Cellular Biochemistry. 102: 829-39. PMID 17914743 DOI: 10.1002/Jcb.21509 |
0.552 |
|
| 2007 |
Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, Gendler SJ, Hollingsworth MA. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Research. 67: 5201-10. PMID 17545600 DOI: 10.1158/0008-5472.Can-06-4647 |
0.758 |
|
| 2006 |
Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends in Cell Biology. 16: 467-76. PMID 16904320 DOI: 10.1016/J.Tcb.2006.07.006 |
0.511 |
|
| 2006 |
Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, Yonezawa S, Hollingsworth MA. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2976-87. PMID 16707592 DOI: 10.1158/1078-0432.Ccr-05-1197 |
0.722 |
|
| Show low-probability matches. |